New opportunities in the treatment of psoriasis and psoriatic arthritis
https://doi.org/10.14412/1995-4484-2018-722-726
Abstract
Objective: to evaluate the efficacy and safety of a selective phosphodiesterase type 4 inhibitor in patients with psoriasis and psoriatic arthritis (PsA).
Subjects and methods. An open uncontrolled study was conducted, which enrolled 20 patients (12 men, 8 women); their mean age was 39.2±14.3 years, the mean duration of psoriasis and PsA was 20.2±12.2 and 10.4±10.2 years, respectively. All the patients included in the study had previously received phototherapy, systemic drugs (methotrexate, aromatic retinoids) with an insufficient effect. Apremilast was administered according to the standard regimen: dose titration during the first 5 days, then 30-mg tablets twice daily for 26 weeks. The efficiency of the therapy was evaluated from changes in PASI, BSA, and sPGA and according to the American College of Rheumatology (ACR) criteria at 14 and 26 weeks and from those in DAS28 at 26 week.
Results and discussion. There were 50 and 75% decreases in PASI respectively in 12 (60%) and 5 (25%) patients, at week 14 of therapy and in 14 (70%) and 7 (35%) patients at week 26. Fourteen (81.2%) patients achieved 20% ACR improvement at week 14. DAS28 decreased on an average by 1.8 at week 26. Adverse events (severe headache, tachycardia) were observed in two patients who were excluded from the study.
Conclusion. Apremilast is an effective and safe agent for the treatment of psoriasis and PsA in patients who have received another systemic therapy proven to be ineffective or they tolerated the latter poorly.
About the Authors
A. A. Kubanov
State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of Russia.
Russian Federation
Russian Federation
3, Korolenko St., Build. 6, Moscow 107076.
A. E. Karamova
State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of Russia.
Russian Federation
3, Korolenko St., Build. 6, Moscow 107076.
Russian Federation
3, Korolenko St., Build. 6, Moscow 107076.
O. G. Artamonova
State Research Center for Dermatovenereology and Cosmetology, Ministry of Health of Russia.
Russian Federation
3, Korolenko St., Build. 6, Moscow 107076.
Russian Federation
3, Korolenko St., Build. 6, Moscow 107076.
References
1. Кубанова АА и др., редакторы. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. Москва: Деловой экспресс; 2016. 768 с. [Kubanova AA et al., editors. Federal'nye klinicheskie rekomendatsii. Dermatovenerologiya 2015: Bolezni kozhi. Infektsii, peredavaemye polovym putem [Federal clinical guidelines. Dermatovenereology 2015: Diseases of the skin. Sexually Transmitted Infections]. Moscow: Delovoi ekspress; 2016. 768 p. (In Russ.)].
2. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14-7. doi: 10.1136/ard.2004.032482
3. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis; development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73. doi: 10.1002/art.21972
4. Федеральные клинические рекомендации по ведению больных псориатическим артритом. Доступно по ссылке: http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf [Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh psoriaticheskim artritom [Federal clinical guidelines for the management of patients with psoriatic arthritis]. Available from: http://www.ismos.ru/guidelines/doc/psoriaticheskij_artrit.pdf (In Russ.)].
5. Wcislo-Dziadecka D, Zbiciak-Nylec M, Brzezinska-Wcislo L, et al. Newer treatments of psoriasis regarding IL23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors. Dermatol Ther. 2017;30(6):12555. doi: 10.1111/dth.12555
6. Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28(7):753-63. doi: 10.1016/j.cellsig.2016.01.007
7. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (ESTEEM1). J Am Acad Dermatol. 2015;73:37-49. doi: 10.1016/j.jaad.2015.03.049
8. Edwards СJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73. doi: 10.1136/annrheumdis-2015-207963
9. Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3). Arthritis Rheum. 2013;65(10 Suppl):S132.
10. Pincelli C, Schafer PH, French LE, et al. Mechanisms underlying the clinical effects of apremilast for psoriasis. J Drugs Dermatol. 2018;17(8):835-40.
11. Galluzzo M, D’Adamio S, Campione E, et al. Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy. Mol Diagn Ther. 2018 (Pub Online: 03 Aug 2018). doi: 10.1007/s40291-018-0354-8
12. Kishimoto M, Komine M, Hioki T, et al. Real-world use of apremilast for patients with psoriasis in Japan. J Dermatol. 2018 (Pub Online: 31 Aug 2018). doi: 10.1111/1346-8138.14617
13. Ceccarelli F, Lucchetti R, Spinelli FR, et al. Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study. Rheumatology. 2018;57(8):1490-1. doi: 10.1093/rheumatology/key145
14. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. J Rheumatol. 2018;57:1253-63. doi: 10.1093/rheumatology/key032
15. Lee EB, Amin M, Egeberg A, et al. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting. J Eur Acad Dermatol Venereol. 2016 Oct;32(10):e393-e394. doi: 10.1111/jdv.15061
Review
For citations:
Kubanov A.A., Karamova A.E., Artamonova O.G. New opportunities in the treatment of psoriasis and psoriatic arthritis. Rheumatology Science and Practice. 2018;56(6):722-726. (In Russ.) https://doi.org/10.14412/1995-4484-2018-722-726
Views:
3653
Email this article 